SSY Group

What SSY Group does

SSY Group Limited is a Cayman-incorporated, Hong Kong-listed (HKEx stock code 2005) pharmaceutical manufacturer with operating history dating to 1940 and over seven decades of brand presence in China. The group is principally engaged in the research, development, manufacturing, and sale of three product categories: finished medicines (primarily intravenous infusion solutions and ampoule injections), bulk pharmaceuticals, and medical materials. Its wholly owned operating subsidiary, Shijiazhuang No.4 Pharmaceutical, anchors production. Manufacturing is conducted on GMP-compliant, fully automated lines with integrated logistics and environmentally efficient (low-cost, low-power, zero-pollution) processes; products such as Arbidol Hydrochloride were developed in-house and have appeared in national treatment protocols, and the group has begun pursuing novel-drug opportunities such as the Class 1 Innovative Drug OPT101.

The company commercializes finished products through direct sales to hospitals and a distributor network spanning domestic China and select international markets across Asia, and is extending internationally following an EU CEP certification for Caffeine in 2025. Strategic moves over the past several years include the spin-off and NEEQ listing of Jiangsu Best New Medical, a 2022 undisclosed target acquisition, and a 2024 framework agreement with Hightide Therapeutics for joint R&D. Two drugs were added to China's National Reimbursement Drug List in 2025, signaling volume expansion via reimbursement access.

Profitability has come under pressure, with reported net profit declining from HK$1,061 million for FY2024 to HK$471 million for FY2025, and H1 profit roughly halving year over year (HK$686M to HK$284M). Revenue is not explicitly disclosed in the supplied materials. Capital markets activity is handled by a small IR team reporting to a deputy general manager, and the board comprises executive, non-executive, and independent non-executive directors under a standard HKEx governance framework.

Name

SSY Group

Legal name

SSY Group Limited

Website

https://ssygroup.com.hk

Company type

Public

Founded year

1940

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

SSY Group Limited is a Hong Kong-listed Chinese pharmaceutical manufacturer with over 70 years of history, producing intravenous infusion solutions, ampoule injections, bulk pharmaceuticals, and medical materials for hospitals and distributors domestically and internationally.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIALAD

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

SECONDARYHLAAAKAB

Drug Product Fill-Finish & Aseptic Manufacturing Services

Healthcare & Life Sciences/Biotechnology & Biologics/Biomanufacturing Services

SECONDARYHLAIABAM

Generic Tender & Government Supply Markets

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

Keywords

• Pharmaceutical manufacturing
• Intravenous infusion solutions
• Ampoule injections
• Bulk pharmaceuticals
• Medical materials

Headquarters

HQ city

Wan Chai

HQ country

Hong Kong SAR China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Finished Pharmaceutical Products: Manufacturing and selling finished medicines, primarily intravenous infusion solutions and ampoule injections to hospitals and distributors
2. Bulk Pharmaceuticals: Production and sale of bulk pharmaceutical ingredients and materials
3. Medical Materials: Manufacturing and distribution of medical materials

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

SSY Group is principally engaged in the research, development, manufacturing and selling of pharmaceutical products, consisting of finished medicines (mainly intravenous infusion solutions and ampoule injections) sold to hospitals and distributors, bulk pharmaceuticals, and medical materials. Production is carried out on advanced automated lines that meet GMP requirements and reach international advanced levels, with green manufacturing advantages in low cost, low power consumption and zero pollution.

Product overview

SSY Group Limited is a pharmaceutical manufacturer with over 7 decades of history, operating a portfolio of pharmaceutical products consisting of three core offerings: (1) Finished Medicines comprising intravenous infusion solutions and ampoule injections sold to hospitals and distributors, (2) Bulk Pharmaceuticals for active pharmaceutical ingredients, and (3) Medical Materials. The company also developed Arbidol Hydrochloride, an antiviral drug included in national treatment guidelines. The Group's production facilities utilize advanced equipment and automated systems meeting GMP requirements.

Differentiator

Problem solved

Functional benefit

Products and services

• Finished Medicines (Intravenous Infusion Solution and Ampoule Injection) Pharmaceutical finished products primarily comprising intravenous infusion solutions and ampoule injections, sold to hospitals and distributors for patient treatment in domestic Chinese and international markets.
• Bulk Pharmaceuticals Active pharmaceutical ingredients and bulk pharmaceutical products manufactured by SSY Group for use in further production of finished dosage forms, sold to pharmaceutical distributors and manufacturers.
• Medical Materials Medical materials produced by SSY Group alongside its pharmaceutical products for healthcare applications, sold through its distribution network.
• Arbidol Hydrochloride Antiviral drug developed by SSY Group, included in the Ministry of Health's Influenza A (H1N1) Treatment Proposal for the treatment of influenza.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Hightide Therapeutics, Inc.minorStrategic or Co-development Partner · 19 December 2024SSY Group entered into a framework agreement with Hightide Therapeutics, Inc. for joint research and development collaboration. This partnership was announced on December 19, 2024, representing SSY Group's strategic move into collaborative drug development initiatives.

Scale indicators6 records

Recent moves10 records

Expansion highlights5 records

Regional players

• China Traditional Chinese Medicine Holdings Co. Ltd. Hong Kong-listed Chinese pharma focused on finished pharmaceutical products distributed primarily into domestic hospital channels. Comparable as a domestic finished-formulation manufacturer competing for hospital procurement.

Broad incumbents

• China Resources Pharmaceutical Group Limited: A large state-owned Chinese pharmaceutical conglomerate manufacturing and distributing a broad portfolio of finished drugs, APIs, and medical materials. Highly comparable as a domestic incumbent competing for hospital formulary and procurement share in the same categories as SSY Group.
• Sino Biopharmaceutical Limited: Hong Kong-listed Chinese pharma with extensive injectable and finished-formulation portfolio plus innovative-drug pipeline. Comparable across SSY's core injectable business and emerging biologics/innovative franchise.
• Shanghai Pharmaceuticals Holding Co., Ltd. A leading Chinese pharmaceutical manufacturer and distributor with both finished dosage and API operations, selling into hospitals nationally. Comparable as a broad-based competitor in formulation manufacturing and Chinese hospital channels.
• CSPC Pharmaceutical Group Limited: Major Hong Kong-listed Chinese pharma manufacturer spanning finished formulations (including injectables), APIs, and innovative drugs. Closely comparable to SSY in product categories (injectables, APIs) and customer base (hospitals/distributors).

Direct peers

• Livzon Pharmaceutical Group Inc. A vertically integrated Chinese pharmaceutical manufacturer producing injectables, APIs, and finished formulations for hospitals. Highly comparable product mix (injectables, APIs) and similar GMP-driven manufacturing positioning as SSY.
• Grand Pharmaceutical (China) Holdings Limited: Chinese pharmaceutical manufacturer with finished formulations and APIs targeting hospital channels, including injectable products. Comparable to SSY in finished injectable and bulk-pharmaceutical categories.
• Kelun Pharmaceutical Co., Ltd. One of China's leading large-volume injection (LVI) manufacturers, directly competing with SSY in IV infusion solutions and ampoule injections sold to hospitals. Highly comparable product-by-product.
• Luye Pharma Group Ltd. Hong Kong-listed Chinese pharma with a portfolio spanning injectable finished dosage forms, oncology, and innovative drugs. Direct peer in injectable manufacturing and channel-to-hospital distribution.

Emerging players

• Hutchison China MediTech Limited (HUTCHMED): Hong Kong-listed Chinese pharma commercializing innovative oncology drugs with growing hospital-channel presence. Comparable as a fellow HK-listed Chinese pharma pursuing an innovative-drug pipeline shift similar to SSY's Hightide/OPT101 direction.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SSY Group